It looks as though Sanofi and Regeneron’s Dupixent will be the first approved treatment for bullous pemphigoid (BP) and have the market to itself for years given that closest rival Argenx has pulled the plug on its program for the autoimmune-related rare skin condition.
Dupixent Set To Dominate Bullous Pemphigoid Space
Argenx has discontinued Vyvgart for the rare skin disease as other potential candidates linger in the very early stages of development.
